ESC 2024 - To date, there have been 5 large RCTs investigating whether timing of antihypertensive medication has an effect on the risk of MACE. Ricky Turgeon shares the results of a meta-analysis of these 5 trials.
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Does taking antihypertensive medication in the evening reduce CV events?
Restart
Resume
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Comments
Overview
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Ricky Turgeon is an assistant professor at the Faculty of Pharmaceutical Sciences at University British Colombia in Vancouver, BC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of this meta-analysis
Release date: 31 August 2024
Recommended
Details
Presenters
Comments
Overview
ESC 2024 - To date, there have been 5 large RCTs investigating whether timing of antihypertensive medication has an effect on the risk of MACE. Ricky Turgeon shares the results of a meta-analysis of these 5 trials.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Ricky Turgeon is an assistant professor at the Faculty of Pharmaceutical Sciences at University British Colombia in Vancouver, BC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of this meta-analysis
Release date: 31 August 2024